tyloxapol drug combination hexadecanol dipalmitoylphosphatidylcholine (Exosurf Neonatal)

protein-free, synthetic surfactant containing dipalmitoylphosphatidylcholine, hexadecanol & tyloxapol; used in treatment of respiratory distress syndrome

Also Known As:

Exosurf Neonatal; dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; Exosurf; colfosceril; dipalmitoylphosphatidylcholine - hexadecanol - tyloxapol; 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, hydroxide, inner salt, 4-oxide, (R)-, mixt. with formaldehyde polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol, and 1-hexadecanol

Networked: 80 relevant articles (14 outcomes, 23 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Moya, Fernando: 2 articles (06/2007 - 03/2007)
2.	Banerjee, R: 2 articles (06/2001 - 01/2001)
3.	Bellare, J R: 2 articles (06/2001 - 01/2001)
4.	Hawtrey, Arthur: 1 article (01/2013)
5.	Smith, Johan: 1 article (01/2013)
6.	van Zyl, Johann M: 1 article (01/2013)
7.	D'Agostino, Ralph: 1 article (06/2007)
8.	Gadzinowski, Janusz: 1 article (06/2007)
9.	Guardia, Carlos: 1 article (06/2007)
10.	Liu, Genzhou: 1 article (06/2007)

Related Diseases

1.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 09/01/1992 - "In conclusion, repeated administration of Exosurf is not equally effective in every treated infant with respiratory distress syndrome (RDS) and complications of prematurity may affect or accompany poor response.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/2000 - "Treatment with intratracheal Exosurf Neonatal in premature infants with established respiratory distress syndrome improves pulmonary gas exchange and decreases the requirement for ventilatory support. " 06/01/1996 - "Eighty-two consecutive, preterm neonates with respiratory distress syndrome, who received Exosurf at < 12 h of age were studied. " 05/01/1995 - "Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf." 10/01/1992 - "Colfosceril in an infant with adult respiratory distress syndrome."
2.	Newborn Respiratory Distress Syndrome 11/01/1991 - "A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome." 06/01/1997 - "Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome." 01/01/1996 - "To compare the efficacy of a synthetic surfactant (Exosurf Neonatal, Burroughs-Wellcome Co) and a modified bovine surfactant extract (Survanta, Ross Laboratories) in the treatment of neonatal respiratory distress syndrome (RDS). " 11/01/1993 - "To compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome. " 05/01/1999 - "This study compares the effects of synthetic (Exosurf) and natural (Survanta) surfactants on infants with neonatal respiratory distress syndrome in Oman. "
3.	Bronchopulmonary Dysplasia 12/01/1990 - "We conclude that improvements in respiratory physiology after a single prophylactic dose of Exosurf result in an increased likelihood of neonatal survival without bronchopulmonary dysplasia." 12/01/1990 - "In the Exosurf group, there was a significant reduction in the combined outcome, neonatal death or survival with bronchopulmonary dysplasia (57 vs 39; p = 0.042), and there was a significant increase in rates of survival without this disease (128 vs 137; p = 0.042). " 07/01/1997 - "Compared with Exosurf, Infasurf treatment resulted in a 62% decrease in the incidence of RDS (Infasurf, 16% vs Exosurf, 42%) and a 70% decrease in RDS death (Infasurf, 1.7% vs Exosurf, 5.4%) but did not increase the incidence of survival without bronchopulmonary dysplasia at 28 days. " 11/01/1993 - "Death or bronchopulmonary dysplasia occurred in 67% of the infants in the Exosurf group and 62% of those in the Survanta group (adjusted relative risk, 1.07; 95% confidence interval, 0.96 to 1.20). " 01/01/2000 - "In individual trials, the use of Exosurf Neonatal resulted in a statistically significant reduction in pneumothorax, patent ductus arteriosus, bronchopulmonary dysplasia (BPD), BPD or death at 28 days, and mortality. "
4.	Pneumothorax 12/01/1993 - "Infants given Exosurf had a significant reduction in the incidence of pulmonary interstitial emphysema (PIE), and a marginal decrease in the incidence of pneumothorax. " 01/01/2000 - "In individual trials, the use of Exosurf Neonatal resulted in a statistically significant reduction in pneumothorax, patent ductus arteriosus, bronchopulmonary dysplasia (BPD), BPD or death at 28 days, and mortality. " 08/01/1991 - "Otherwise no significant difference was noted between Exosurf and human surfactant in radiologic severity of respiratory distress syndrome or in the prevalence of pulmonary interstitial emphysema, pneumothorax, and bronchopulmonary dysplasia. " 03/01/2007 - "Animal-derived surfactants that contain surfactant proteins (Survanta, Infasurf, and Curosurf) perform clinically better than Exosurf, a synthetic surfactant containing only phospholipids, primarily in outcomes related to acute management of respiratory distress syndrome (RDS; faster weaning and pneumothorax) but not in overall mortality or incidence of bronchopulmonary dysplasia (BPD). "
5.	Lung Injury 04/01/1990 - "Thus, we failed to show an acutely beneficial effect of aerosolized Exosurf in OA-induced lung injury; Exosurf did, however, appear to provide protection against some of the consequences of repeated lung injury." 06/01/1996 - "We conclude that Exosurf is more effective when administered by lavage in this lung injury model. " 09/01/1999 - "We tested the hypothesis that the nonlipid components of Exosurf, tyloxapol (TY), and cetyl alcohol (CA), protect against hyperoxic lung injury by induction of the animals' endogenous antioxidant defenses. " 04/01/1990 - "We studied the effects of an artificial surfactant, Exosurf, administered as an aerosol on respiratory system compliance (Crs), total respiratory resistance (RT), and gas exchange (PO2) in anesthetized, paralyzed sheep with oleic acid (OA)-induced lung injury. "

Related Drugs and Biologics

1.	Surface-Active Agents (Surfactants)
2.	beractant (Survanta)
3.	tyloxapol drug combination hexadecanol dipalmitoylphosphatidylcholine (Exosurf Neonatal)
4.	colfosceril palmitate
5.	Oxygen (Dioxygen)
6.	Gases
7.	Phospholipids (Phosphatides)
8.	calfactant (Infasurf)
9.	Aerosols
10.	lucinactant

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)
3.	Investigational Therapies (Experimental Therapy)
4.	Mechanical Ventilators (Ventilator)
5.	Positive-Pressure Respiration (Positive End-Expiratory Pressure)